Search

Sanofi SA

Gesloten

SectorGezondheidszorg

84.57 -0.21

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

84.09

Max

84.94

Belangrijke statistieken

By Trading Economics

Inkomsten

1.1B

2.9B

Verkoop

129M

11B

K/W

Sectorgemiddelde

16.656

37.257

EPS

1.59

Dividendrendement

4.52

Winstmarge

27.303

Werknemers

82,878

EBITDA

-881M

1.9B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+24.85% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.52%

2.94%

Volgende Winsten

24 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

463M

105B

Vorige openingsprijs

84.78

Vorige sluitingsprijs

84.57

Nieuwssentiment

By Acuity

28%

72%

90 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Sanofi SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 okt 2025, 10:40 UTC

Acquisities, Fusies, Overnames

Santander UK CEO Stands Down Ahead of TSB Integration

1 okt 2025, 08:54 UTC

Belangrijke Marktbewegers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

4 sep 2025, 08:58 UTC

Belangrijke Marktbewegers

Sanofi Shares Sink as Experimental Drug Results Disappoint

4 aug 2025, 10:06 UTC

Belangrijke Marktbewegers

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 jul 2025, 06:00 UTC

Winsten

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

6 okt 2025, 08:15 UTC

Marktinformatie

Sanofi's Profitability Stronger Than It Looks -- Market Talk

3 okt 2025, 14:10 UTC

Marktinformatie

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

3 okt 2025, 10:06 UTC

Acquisities, Fusies, Overnames

Santander's Regnier Says He Is Leaving to Allow Successor to Lead TSB Integration

3 okt 2025, 10:03 UTC

Acquisities, Fusies, Overnames

Santander: Appointment Process to Find Successor Has Started

3 okt 2025, 10:02 UTC

Acquisities, Fusies, Overnames

Santander: Mike Regnier to Step Down by 1Q 2026

3 okt 2025, 10:01 UTC

Acquisities, Fusies, Overnames

Santander UK CEO to Step Down

1 okt 2025, 07:53 UTC

Marktinformatie

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

5 sep 2025, 08:24 UTC

Marktinformatie

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5 sep 2025, 06:55 UTC

Marktinformatie

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

28 aug 2025, 09:00 UTC

Marktinformatie

Santander Could Deliver Even Higher Returns -- Market Talk

6 aug 2025, 05:02 UTC

Acquisities, Fusies, Overnames

Sanofi Completes the Acquisition of Vigil Neuroscience

6 aug 2025, 05:00 UTC

Acquisities, Fusies, Overnames

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 aug 2025, 13:16 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 12:40 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 jul 2025, 08:15 UTC

Marktinformatie
Winsten

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 jul 2025, 05:56 UTC

Marktinformatie
Winsten

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 jul 2025, 05:30 UTC

Winsten

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Business Operating Profit EUR2.46B

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Adj EPS EUR1.59

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

Sanofi SA Prognose

Koersdoel

By TipRanks

24.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 105.92 EUR  24.85%

Hoogste 121.052 EUR

Laagste 92.806 EUR

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sanofi SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

12

Buy

2

Hold

0

Sell

Technische score

By Trading Central

91.3 / 96.1Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

90 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat